vs
LivaNova PLC（LIVN）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是ROGERS CORP的1.8倍（$360.9M vs $200.5M），LivaNova PLC净利率更高（8.6% vs 2.2%，领先6.3%），LivaNova PLC同比增速更快（12.1% vs 5.2%），LivaNova PLC自由现金流更多（$50.2M vs $1.1M），过去两年LivaNova PLC的营收复合增速更高（10.6% vs -3.3%）
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
LIVN vs ROG — 直观对比
营收规模更大
LIVN
是对方的1.8倍
$200.5M
营收增速更快
LIVN
高出6.9%
5.2%
净利率更高
LIVN
高出6.3%
2.2%
自由现金流更多
LIVN
多$49.1M
$1.1M
两年增速更快
LIVN
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $360.9M | $200.5M |
| 净利润 | $30.9M | $4.5M |
| 毛利率 | 65.2% | 32.2% |
| 营业利润率 | 11.8% | — |
| 净利率 | 8.6% | 2.2% |
| 营收同比 | 12.1% | 5.2% |
| 净利润同比 | -44.7% | 421.4% |
| 每股收益（稀释后） | $0.57 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIVNROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $360.9M | $201.5M | ||
| Q3 25 | $357.8M | $216.0M | ||
| Q2 25 | $352.5M | $202.8M | ||
| Q1 25 | $316.9M | $190.5M | ||
| Q4 24 | $321.8M | $192.2M | ||
| Q3 24 | $318.1M | $210.3M | ||
| Q2 24 | $318.6M | $214.2M |
净利润LIVNROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $30.9M | $4.6M | ||
| Q3 25 | $26.8M | $8.6M | ||
| Q2 25 | $27.2M | $-73.6M | ||
| Q1 25 | $-327.3M | $-1.4M | ||
| Q4 24 | $55.9M | $-500.0K | ||
| Q3 24 | $33.0M | $10.7M | ||
| Q2 24 | $16.3M | $8.1M |
毛利率LIVNROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 65.2% | 31.5% | ||
| Q3 25 | 68.4% | 33.5% | ||
| Q2 25 | 67.8% | 31.6% | ||
| Q1 25 | 69.7% | 29.9% | ||
| Q4 24 | 68.2% | 32.1% | ||
| Q3 24 | 70.8% | 35.2% | ||
| Q2 24 | 68.7% | 34.1% |
营业利润率LIVNROG
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 3.5% | ||
| Q3 25 | 15.1% | 7.3% | ||
| Q2 25 | 15.4% | -33.3% | ||
| Q1 25 | 15.3% | -0.2% | ||
| Q4 24 | 11.5% | -6.6% | ||
| Q3 24 | 11.2% | 6.9% | ||
| Q2 24 | 12.6% | 5.3% |
净利率LIVNROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 8.6% | 2.3% | ||
| Q3 25 | 7.5% | 4.0% | ||
| Q2 25 | 7.7% | -36.3% | ||
| Q1 25 | -103.3% | -0.7% | ||
| Q4 24 | 17.4% | -0.3% | ||
| Q3 24 | 10.4% | 5.1% | ||
| Q2 24 | 5.1% | 3.8% |
每股收益（稀释后）LIVNROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.57 | $0.20 | ||
| Q3 25 | $0.49 | $0.48 | ||
| Q2 25 | $0.50 | $-4.00 | ||
| Q1 25 | $-6.01 | $-0.08 | ||
| Q4 24 | $1.04 | $-0.04 | ||
| Q3 24 | $0.60 | $0.58 | ||
| Q2 24 | $0.30 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.6M | $195.8M |
| 总债务越低越好 | $376.1M | — |
| 股东权益账面价值 | $1.2B | $1.2B |
| 总资产 | $2.6B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.31× | — |
8季度趋势，按日历期对齐
现金及短期投资LIVNROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $635.6M | $197.0M | ||
| Q3 25 | $646.1M | $167.8M | ||
| Q2 25 | $593.6M | $157.2M | ||
| Q1 25 | $738.4M | $175.6M | ||
| Q4 24 | $428.9M | $159.8M | ||
| Q3 24 | $346.4M | $146.4M | ||
| Q2 24 | $329.2M | $119.9M |
总债务LIVNROG
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — |
股东权益LIVNROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B |
总资产LIVNROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.6B | $1.4B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.6B | $1.5B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B |
负债/权益比LIVNROG
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $50.2M | $1.1M |
| 自由现金流率自由现金流/营收 | 13.9% | 0.5% |
| 资本支出强度资本支出/营收 | 8.9% | 2.3% |
| 现金转化率经营现金流/净利润 | 2.67× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $173.3M | $70.1M |
8季度趋势，按日历期对齐
经营现金流LIVNROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $82.4M | $46.9M | ||
| Q3 25 | $85.1M | $28.9M | ||
| Q2 25 | $62.9M | $13.7M | ||
| Q1 25 | $24.0M | $11.7M | ||
| Q4 24 | $78.7M | $33.7M | ||
| Q3 24 | $51.0M | $42.4M | ||
| Q2 24 | $43.4M | $22.9M |
自由现金流LIVNROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $50.2M | $42.2M | ||
| Q3 25 | $62.2M | $21.2M | ||
| Q2 25 | $47.8M | $5.6M | ||
| Q1 25 | $13.2M | $2.1M | ||
| Q4 24 | $68.3M | $18.3M | ||
| Q3 24 | $32.8M | $25.2M | ||
| Q2 24 | $31.2M | $8.8M |
自由现金流率LIVNROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 13.9% | 20.9% | ||
| Q3 25 | 17.4% | 9.8% | ||
| Q2 25 | 13.6% | 2.8% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 21.2% | 9.5% | ||
| Q3 24 | 10.3% | 12.0% | ||
| Q2 24 | 9.8% | 4.1% |
资本支出强度LIVNROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 8.9% | 2.3% | ||
| Q3 25 | 6.4% | 3.6% | ||
| Q2 25 | 4.3% | 4.0% | ||
| Q1 25 | 3.4% | 5.0% | ||
| Q4 24 | 3.2% | 8.0% | ||
| Q3 24 | 5.7% | 8.2% | ||
| Q2 24 | 3.8% | 6.6% |
现金转化率LIVNROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.67× | 10.20× | ||
| Q3 25 | 3.18× | 3.36× | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | 3.96× | ||
| Q2 24 | 2.65× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
ROG
暂无分部数据
